First patient dosed in new pancreatic cancer trial
Filed with ASX · · 2 pages · English
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Share Purchase Plan Raises $2.65 Million
- Positive ACCENT Trial Topline Data Released
- Capital Raising Presentation
- Amplia announces A$25m Placement and Launches A$2.5m SPP
- Second Complete Response in ACCENT Pancreatic Cancer Trial
Later from Amplia Therapeutics
- Amplia Receives R&D Tax Rebate Totalling $3.77 Million
- Positive Response from US FDA to Amplia's Type D Meeting
- Half Yearly Report and Accounts
- Key Narmafotinib Patent Granted in the U.S.
- Amplia Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum December 11th
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics